CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $448,182 | +134.7% | 15,070 | +42.2% | 0.00% | +100.0% |
| Q2 2023 | $190,994 | +9.0% | 10,599 | -2.9% | 0.00% | 0.0% |
| Q1 2023 | $175,279 | -9.8% | 10,914 | +2.8% | 0.00% | 0.0% |
| Q4 2022 | $194,291 | -2.9% | 10,617 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $200,000 | +6.4% | 10,178 | +1.0% | 0.00% | 0.0% |
| Q2 2022 | $188,000 | -23.9% | 10,078 | +15.9% | 0.00% | 0.0% |
| Q4 2021 | $247,000 | – | 8,693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |